Art. -Nr.: HY-N0054

Osthole

(Synonyms: Osthol; NSC 31868)

16 Cited Publications

Kundenbewertung

Based on 16 publication(s) in Google Scholar

Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of histamine H₁ receptor activity. Osthole also suppresses the secretion of HBV in cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.98%
CAS. Nr.: 484-12-8
Formel: C₁₅H₁₆O₃
Molecular Weight:244.29

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Osthole Chemical Structure

CAS. Nr.: 484-12-8

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (16)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of histamine H₁ receptor activity. Osthole also suppresses the secretion of HBV in cells.

IC₅₀ & Target

Histamine H₁ receptor^[1]

Alle Histamine Receptor Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A10	IC₅₀	13.6 μM Compound: 5	Antiproliferative activity against rat A10 Antiproliferative activity against rat A10	[PMID: 21627108]
A-431	IC₅₀	23.2 μM Compound: 1	Cytotoxicity against human A431 cells after 24 hrs by MTT assay Cytotoxicity against human A431 cells after 24 hrs by MTT assay	[PMID: 25062005]
A549	IC₅₀	46.2 μM Compound: 1	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 25062005]
COLO 205	IC₅₀	>60 μM Compound: 1	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 25062005]
HCT-116	IC₅₀	30.2 μM Compound: 1	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 25062005]
HeLa	IC₅₀	1.6 μM Compound: 1	Inhibition of CRM1-mediated hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as nucleus localization after 12 hrs by indirect fluorescent antibody technique Inhibition of CRM1-mediated hemagglutininin-tagged HIV1 Rev protein nuclear export in human HeLa cells assessed as nucleus localization after 12 hrs by indirect fluorescent antibody technique	[PMID: 20493693]
HepG2	IC₅₀	161.4 μM Compound: Osthole I	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25461322]
KB	IC₅₀	12 μg/mL Compound: 1 (Osthol)	Compound was tested for its cytotoxicity against KB cells Compound was tested for its cytotoxicity against KB cells	10.1016/0960-894X(96)00315-0
MCF7	IC₅₀	25.8 μM Compound: 5, Osthole	Anticancer activity against human MCF7 assessed as inhibition of cell growth by MTT assay Anticancer activity against human MCF7 assessed as inhibition of cell growth by MTT assay	[PMID: 21051232]
MDA-MB-231	IC₅₀	30.2 μM Compound: 5, Osthole	Anticancer activity against human MDA-MB-231 assessed as inhibition of cell growth by MTT assay Anticancer activity against human MDA-MB-231 assessed as inhibition of cell growth by MTT assay	[PMID: 21051232]
MM46	IC₅₀	8.6 μg/mL Compound: 1 (Osthol)	Compound was tested for its cytotoxicity against MM46 cells Compound was tested for its cytotoxicity against MM46 cells	10.1016/0960-894X(96)00315-0
P388	IC₅₀	3.1 μg/mL Compound: 1 (Osthol)	Compound was tested for its cytotoxicity against P-388 cells Compound was tested for its cytotoxicity against P-388 cells	10.1016/0960-894X(96)00315-0
PC-3	IC₅₀	24.8 μM Compound: 1	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 25062005]
RAW264.7	IC₅₀	113.04 μM Compound: Osthole	Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 38422703]
RAW264.7	IC₅₀	12.4 μM Compound: 15	Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs	[PMID: 25621853]
RAW264.7	IC₅₀	146.1 μM Compound: Osthole	Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 38422703]
SH-SY5Y	EC₅₀	26.45 μM Compound: Osthole	Neuroprotection against oxygen-glucose deprivation-induced toxicity in human SH-SY5Y cells assessed as cytoprotection by MTT assay Neuroprotection against oxygen-glucose deprivation-induced toxicity in human SH-SY5Y cells assessed as cytoprotection by MTT assay	[PMID: 33132198]
SH-SY5Y	EC₅₀	33.26 μM Compound: Osthole	Neuroprotection against H202-induced toxicity in human SH-SY5Y cells assessed as cytoprotection by MTT assay Neuroprotection against H202-induced toxicity in human SH-SY5Y cells assessed as cytoprotection by MTT assay	[PMID: 33132198]
T47D	IC₅₀	42.4 μM Compound: 1	Cytotoxicity against human T47D cells after 24 hrs by MTT assay Cytotoxicity against human T47D cells after 24 hrs by MTT assay	[PMID: 25062005]
V79	IC₅₀	57 μM Compound: 1 (Osthol)	Cytotoxicity against V-79 cells Cytotoxicity against V-79 cells	10.1016/0960-894X(96)00315-0

In Vitro

Osthole (p<0.0001) and Fexofenadine (p<0.001) inhibit increased HRH-1 mRNA expression induced by histamine in the study group. This result is also observed in cells cultured with histamine/Osthole; where combined substances decreased HRH-1 mRNA expression compared to histamine (p<0.0001)^[1]. Assessment of cell viability does not detect obvious toxicity when Osthole is used at a dose up to 100 μM. However, when the dose reached 500 μM, Osthole started to show toxic effect. Based on these observations, Osthole is used in all in vitro studies at the dose range of 10 to 100 μM. Osthole dose-dependently promotes osteoblast differentiation, as shown by the upregulation of osteoblast differentiation marker genes such as type I collagen (col1), bone sialoprotein (BSP) and osteocalcin (OC) (2 days of culture). Osthole promotes ALP activity in mouse primary osteoblasts in a dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Subcutaneous injection of Osthole at a dose of 5 mg/kg per day onto mouse calvariae significantly stimulates local bone formation, as shown by histologic analysis of calvarial samples harvested 2 weeks after the last injection and stained with H&E orange G. Histomorphometric analysis reveals that Osthole has a significant effect on bone formation as potent as the positive control, the microtubule inhibitor TN-16. This effect, however, is not seen when Osthole is used at a dose of 1 mg/kg per day. Intraperitoneal injection of Osthole for 8 weeks significantly reverses bone loss in the ovariectomized rats. Histologic examination of the L4samples stained with trinitrophenol poinsettia demonstrates a partial recovery of the trabecular structure in ovariectomized rats treated with Osthole. Histomorphometric analysis shows that treatment with Osthole significantly increases total BMD, trabecular bone volume, and trabecular thickness and decreases trabecular separation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 484-12-8
Appearance Solid
Molecular Weight 244.29
Formel C₁₅H₁₆O₃
Color White to off-white
SMILES

O=C1C=CC2=CC=C(OC)C(C/C=C(C)\C)=C2O1
Synonyms

Osthol; NSC 31868
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (16)

All IFRT-PCRIHCWB

Sort by:

Journal Impact Factor

Acta Pharmacol Sin

Osthole prevents tamoxifen-induced liver injury in mice. [Abstract]

2019 May;40(5):608-619. PMID: 30315252

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):608-619. [Abstract]

Osthole reduces TMX-induced oxidative stress.

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):608-619. [Abstract]

Osthole significantly increases the expression of antioxidant genes (GPX1, SOD2). Mice are intraperitoneally injected with osthole (100 mg/kg).

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):608-619. [Abstract]

Osthole significantly increases the expression of antioxidant genes (GCL-c, and G6pdh. Mice are intraperitoneally injected with osthole (100 mg/kg).

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):608-619. [Abstract]

Osthole significantly suppresses the expression of pro-oxidant genes (NOX2 and ACOX). Mice are intraperitoneally injected with osthole (100 mg/kg).

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):608-619. [Abstract]

Osthole reduces the TMX-induced inflammatory response. Mice are intraperitoneally injected with Osthole (100 mg/kg).

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):608-619. [Abstract]

Osthole reduces the TMX-induced inflammatory response. Mice are intraperitoneally injected with Osthole (100 mg/kg)

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):608-619. [Abstract]

Mice are intraperitoneally injected with Osthole (100 mg/kg). After 24h, TMX (90mg/kg) is administered to mice. Mice are sacrificed 8 h after the TMX injections. Western blot analyses of the liver homogenates are performed.
Acta Pharmacol Sin

Osthole prevents acetaminophen-induced liver injury in mice. [Abstract]

2018 Jan;39(1):74-84. PMID: 29022574

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2018 Jan;39(1):74-84. [Abstract]

Osthole inhibits the metabolic activation of APAP and promotes APAP clearance. Hepatic SULT2A1 and UGT1A1 levels are determined by Western blotting.
Acta Pharmacol Sin

Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways. [Abstract]

2017 Aug;38(8):1120-1128. PMID: 28603288

Osthole purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2017 Aug;38(8):1120-1128. [Abstract]

Osthole attenuates the phosphorylation of p38 in TNBS-induced colitis. Mice receive Osthole intraperitoneally at 100 mg/kg once daily starting at three days before being exposed to TNBS treatments and until the end of the experiments. Colitis is induced by infusing a 100 μL enema of TNBS (2.8 mg) in 50% ethanol into the colonic lumen. Western blot analysis of the colonic mucosa homogenates is performed 2 d after the initial rectal TNBS administration.
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Int J Mol Sci

GelMA Hydrogel as a Promising Delivery System for Osthole in the Treatment of Rheumatoid Arthritis: Targeting the miR-1224-3p/AGO1 Axis. [Abstract]

2023 Aug 25;24(17):13210. PMID: 37686018
Int Immunopharmacol

Osthole alleviates neuropathic pain by suppressing astrocytes activation and associated inflammatory responses via the PKCδ/TRPV4 signaling pathway. [Abstract]

2025 Sep 10:165:115453. PMID: 40934539
Invest Ophthalmol Vis Sci

Osthole Reduces Mouse IOP Associated With Ameliorating Extracellular Matrix Expression of Trabecular Meshwork Cell. [Abstract]

2020 Aug 3;61(10):38. PMID: 32821914
J Funct Foods

2023 Sep, 108, 105737.
Sci Rep

Osthol ameliorates obesity-associated lipid metabolic disorders by inhibiting ADRA1D-dependent Th17 cell differentiation. [Abstract]

2025 Oct 21;15(1):36691. PMID: 41120583
J Neurosci Res

Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein. [Abstract]

2019 Dec;97(12):1689-1705. PMID: 31420910
Front Physiol

Osthole Ameliorates Renal Fibrosis in Mice by Suppressing Fibroblast Activation and Epithelial-Mesenchymal Transition. [Abstract]

2018 Nov 21:9:1650. PMID: 30524310

Osthole purchased from MedChemExpress. Usage Cited in: Front Physiol. 2018 Nov 21:9:1650. [Abstract]

OST suppress activation of NRK-49F cells. NRK-49F are preincubated with OST for 30 min before TGFβ1 (5 ng/ml) and are harvested 24 h after TGFb1 stimulation. Western blot analyses of a-SMA, Col I (collagen I) and FN (fibronectin) are showed.

Osthole purchased from MedChemExpress. Usage Cited in: Front Physiol. 2018 Nov 21:9:1650. [Abstract]

Representative micrographs of immunofluorescent staining of FN (red) and a-SMA (green) with the treatment of TGFβ1 and OST.

Osthole purchased from MedChemExpress. Usage Cited in: Front Physiol. 2018 Nov 21:9:1650. [Abstract]

Western blot analyses (E) of PCNA, cyclin D1 and p21 cip1 in the treatment of FBS and OST.
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Biol Pharm Bull

Osthole Improves Cognitive Function of Vascular Dementia Rats: Reducing Aβ Deposition via Inhibition NLRP3 Inflammasome. [Abstract]

2020;43(9):1315-1323. PMID: 32879205
SSRN

2025 May 22.
J Healthc Eng

The Role of Osthole on TGF- β-Induced Lung Epithelium Apoptosis Injury and Epithelial-Mesenchymal Transition-Mediated Airway Remodeling in Pediatric Asthma. [Abstract]

2022 Mar 24;2022:7099097. PMID: 35368934
SSRN

2021 Feb.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (409.35 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0935 mL

20.4675 mL

40.9350 mL

5 mM

0.8187 mL

4.0935 mL

8.1870 mL

10 mM

0.4093 mL

2.0467 mL

4.0935 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Konzentration

Volumen

Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

Peripheral blood samples are collected from participants between 7.00 and 9.00 a.m. on the first study day and these are concentrated in grouping tubes with K₃EDTA. Fresh PBMCs are then prepared. Isolated cells are seeded on 24-well plates at 1×10⁶ per well with RPMI-1640 and supplemented with 1% heat inactivated human AB serum, 1% gentamicin and 0.25% PHA. Active reagents are added to each well after 24 h and pure medium formed the control for each substance. Cells are then harvested after a further three days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Four-week-old ICR Swiss mice are injected subcutaneously over the calvarial surface with or without the treatment of Osthole twice a day for 5 consecutive days at the doses of 1 and 5 mg/kg per day (3 mice per group). Microtubule inhibitor TN-16 is used as a positive control (5 mg/kg per day, by subcutaneous injection, twice a day for 2 days; 3 mice per group). All mice are euthanized 3 weeks after treatment, and calvariae are dissected, fixed in 10% phosphate-buffered formalin for 2 days, decalcified in 10% EDTA for 2 weeks, and embedded in paraffin. Histologic sections are cut and stained with hematoxylin and eosine orange G. New bone area over the calvarial surface is quantified by histomorphometry using the OsteoMeasure System. To measure mineral appositional rate (MAR) and bone-formation rate (BFR), double calcein labeling is performed at days 7 and 14 by intraperitoneal injection (20 mg/kg), and mice are euthanized 7 days after the second labeling. The labeling is examined in plastic sections. The dissected calvarial samples are fixed in 75% ethanol and embedded in methyl methacrylate. Unstained transverse sections (3 µm thick) are examined with a fluorescent microscope. MAR and BFR are measured using the OsteoMeasure System.
Rats^[2]
Thirty 6-month-old female Sprague-Dawley rats are used. After anesthesia with intraperitoneal nembutal injection (30 mg/kg), the rats are randomized by body weight into three groups for the surgery (n=10/group): group 1: sham surgery followed by PBS vehicle treatment (sham+VEH); group 2: ovariectomy followed by vehicle treatment (OVX+VEH); and group 3: ovariectomy followed by Osthole treatment (OVX+OST). The treatment is started 1 month after surgery and continued for 8 weeks. Vehicle or Osthole (100 mg/kg per day) is administered orally once a day for 8 weeks. Before rats are euthanized at the end of the experiments, the total bone mineral density (BMD, g/m²) is measured using dual-energy X-ray absorptiometry. The fourth lumbar vertebrae (L4) then are dissected for histomorphometric and micro-computed tomographic (µCT) analysis, and the left femoral shafts are used for biomechanical testing.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kordulewska NK, et al. Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H1 receptor, COX-2, NF-κB, CCR1, chemokine CCL5/RANTES and interleukin-1β in PBMC allergic and non-allergic patients. Immunobiology. [Content Brief]

[2]. Tang DZ, et al. Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res. 2010 Jun;25(6):1234-45. [Content Brief]

[3]. Sun W, et al. Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways. Acta Pharmacol Sin. 2017 Aug;38(8):1120-1128. [Content Brief]

[4]. Zhang ZR, et al. Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine. Evid Based Complement Alternat Med. 2015;2015:919616. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0935 mL	20.4675 mL	40.9350 mL	102.3374 mL
	5 mM	0.8187 mL	4.0935 mL	8.1870 mL	20.4675 mL
	10 mM	0.4093 mL	2.0467 mL	4.0935 mL	10.2337 mL
	15 mM	0.2729 mL	1.3645 mL	2.7290 mL	6.8225 mL
	20 mM	0.2047 mL	1.0234 mL	2.0467 mL	5.1169 mL
	25 mM	0.1637 mL	0.8187 mL	1.6374 mL	4.0935 mL
	30 mM	0.1364 mL	0.6822 mL	1.3645 mL	3.4112 mL
	40 mM	0.1023 mL	0.5117 mL	1.0234 mL	2.5584 mL
	50 mM	0.0819 mL	0.4093 mL	0.8187 mL	2.0467 mL
	60 mM	0.0682 mL	0.3411 mL	0.6822 mL	1.7056 mL
	80 mM	0.0512 mL	0.2558 mL	0.5117 mL	1.2792 mL
	100 mM	0.0409 mL	0.2047 mL	0.4093 mL	1.0234 mL

Keywords

Osthole

16 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Osthole

Anti-Infection Compound Library

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Osthole

Alle Histamine Receptor Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Osthole Related Classifications

Art. -Nr.: HY-N0054